Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

US Denies Approval for Creat's $1.5 Billion Acquisition of Germany's Biotest

publication date: Nov 8, 2017

Creat Group of China has withdrawn its current $1.5 billion offer to acquire Biotest, a German blood plasma products corporation, because US regulators refused to approve the deal. According to Bloomberg, the Committee on Foreign Investment in the United States was worried that a China corporation would have access to US donor information. Creat and Biotest said the acquisition can not be completed under the current structure, but the two companies hope to forge a new agreement that will satisfy US regulators. More details....

Stock Symbol: (DE: BIOG)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.